PRESENTATION

Q2 2025 — Presentation

Q2 2025PDF · 34 pages2.1 MB
Second-Quarter 2025
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
July 29, 2025

-- 1 of 34 --

Agenda
2
Agenda
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 34 --

3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

-- 3 of 34 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 34 --

5
Q2 performance in-line with expectations
$15.8B
Q2 Worldwide Sales
Results reflect strength in Oncology, Animal Health,
and increasing contributions from new launches
Q2 Non-GAAP EPS1,2
$2.13
1. Q2 2025 includes a charge of $0.07 per share related to the closing of a license agreement with Hengrui Pharma 2. Q2 2025 GAAP EPS of $1.76

-- 5 of 34 --

6
Driving value by progressing innovative pipeline
• 	Received 10 th earlier stage approval for KEYTRUDA
• 	Presented data at ASCO from multiple novel candidates and broad oncology portfolio
Oncology
• 	FDA approved and ACIP recommended ENFLONSIA for prevention of RSV in infants younger than
8 months of age born during or entering their first RSV season
• 	FDA accepted NDA for doravirine + islatravir for HIV-1 treatment in adults with suppressed virus
• 	Presented Phase 2 data at IAS for MK-8527 for PrEP	Infectious Disease
• 	Positive topline results for enlicitide in hyperlipidemia in first two CORALreef studies
• 	Positive topline results for WINREVAIR in recently diagnosed PAH in HYPERION study
• 	Supplemental BLA accepted for WINREVAIR based on ZENITH studyCardiopulmonary

-- 6 of 34 --

77
Ohtuvayre® is the first novel inhaled COPD maintenance
treatment in more than 20 years, a large disease area with
significant unmet medical need
Significant potential to positively impact patients and create
shareholder value
Multibillion dollar commercial opportunity with potential to
drive both near- and long-term revenue growth
Continuing to advance science-led strategy through pending acquisition
of Verona Pharma
Science-driven business development that strengthens and
complements cardiopulmonary portfolio

-- 7 of 34 --

88	Excludes ongoing Phase 3 studies for marketed products including KEYTRUDA, Lenvima, Lynparza, Verquvo, LAGEVRIO and WELIREG. Reflects select late-phase programs.
1. Collaboration with Moderna 2. Collaboration with Taiho and Astex 3. Collaboration with Kelun Biotech 4. Collaboration with Daiichi Sankyo 5. Collaboration with Gilead
Entering period of rapid transformation with expansive late-phase pipeline
Oncology 	Vaccines & Infectious Disease 	Other Pharma
subQ pembrolizumab + berahyaluronidase alfa
intismeran autogene 1
nemtabrutinib
bomedemstat
opevesostat
MK-10842
sacituzumab tirumotecan 3
zilovertamab vedotin
patritumab deruxtecan4
ifinatamab deruxtecan 4
raludotatug deruxtecan 4
doravirine + islatravir
islatravir + lenacapavir5
MK-8527
V181
enlicitide decanoate
tulisokibart
MK-3000
Broad late-phase pipeline	Recent launches

-- 8 of 34 --

9
Delivering the
next wave of
innovation
Well positioned to successfully navigate
the KEYTRUDA LOE period
Executing Business Development
Actively pursuing additional science-driven
value-creating transactions
Launching New Growth Drivers
>$50B commercial opportunity by mid-2030s from
recent launches and late-phase pipeline
Advancing Early- and Late-Phase Pipeline
Tripled late-phase pipeline since 2021

-- 9 of 34 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
10

-- 10 of 34 --

11
Q2 performance driven by robust demand for our innovative portfolio
1. Worldwide Sales includes Other Revenue 2. Excludes sales of GARDASIL in China of $1.3 billion in 2Q24
Human Health
$14.1B-2% nominal
-3% ex-FX
+7% ex-GARDASIL China2 , nominal & ex-FX
$15.8B-2% nominal & ex-FX
+7% ex-GARDASIL China 2 , nominal & ex-FX
WORLDWIDE SALES1 Animal Health
$1.6B+11% nominal & ex-FX

-- 11 of 34 --

12
Oncology: KEYTRUDA continues to benefit patients and drive growth
KEYTRUDA sales of $8.0B increased 9%,
driven by robust demand from metastatic
indications and increased uptake in earlier-
stage cancers
‒ 	Growth driven by usage in tumors
predominantly affecting women, including those
with certain breast, cervical and endometrial
cancers
‒ 	Increased use of KEYTRUDA in combination with
enfortumab vedotin in first-line, locally advanced
urothelial cancer
‒ 	Positive feedback from HCPs following recent
launch of KN-689 in certain patients with locally
advanced head and neck cancer
2Q23 	2Q24 	2Q25
$6.3B
+21%
$8.0B
+9%	$7.3B
+21%1
Growth rates exclude the impact of foreign exchange.
1. ~4 percentage points of negative impact of foreign exchange substantially all of which was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases.

-- 12 of 34 --

13
Oncology: Strong growth across broad portfolio
WELIREG sales grew 29%, driven by increased
uptake in certain adult patients with
previously treated advanced RCC in the U.S.
Lynparza 1 sales grew 15%, primarily due to
higher demand in the U.S. and certain
international markets
Lenvima 2 sales grew 5%, primarily due to
higher sales in the U.S. reflecting higher
demand, partially offset by lower pricing
Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
2Q23 	2Q24 	2Q25
$317M
+4%
$310M
+15%
$370M
+15%
2Q23 	2Q24 	2Q25
$249M
+4%
$242M
+6%
$265M
+5%
2Q23 	2Q24 	2Q25
$126M
+150%
$50M
+89%
$162M
+29%

-- 13 of 34 --

14
Vaccines: GARDASIL protecting lives from HPV-related cancers
GARDASIL sales of $1.1B decreased 55%, driven
primarily by China
‒ 	Outside the U.S. and China, decline driven by lower
sales in Japan reflecting expiration of
reimbursement for catch-up cohort and timing of
public sector purchases in certain international
markets
‒ 	In the U.S., growth of 2% driven by price and higher
demand, partially offset by CDC purchasing
patterns
2Q23 	2Q24 	2Q25
$2.5B
+4%
$1.1B
-55%
$2.5B
+53%
Growth rates exclude the impact of foreign exchange.

-- 14 of 34 --

15
Vaccines: Growth across pneumococcal vaccine portfolio
CAPVAXIVE 1 sales of $129M driven by demand
from retail pharmacies and non-retail customers
VAXNEUVANCE sales of $229M increased 20%
‒ 	In the U.S., growth benefitted by ~$60M from CDC
stockpile activity2 , partially offset by competitive
pressures
‒ 	Outside the U.S., growth in certain international
markets offset by competitor preferential
recommendation in Japan
2Q23 	2Q24 	2Q25
$1.7B
+40%
2Q23 	2Q24 	2Q25
$129M
$168M $189M
+16%
$229M
+20%
Growth rates exclude the impact of foreign exchange.
1. Launched in 3Q24 2. Benefit to VAXNEUVANCE was offset by a draw down of CDC stockpile inventory for ROTATEQ and VARIVAX resulting in a net neutral transaction

-- 15 of 34 --

16
ENFLONSIA: Excited to bring new option for RSV prevention in infants
First and only RSV preventive option for administration
to infants using same dose regardless of weight
Compelling clinical data and operational simplicity
make it an important option
Initial orders received in July

-- 16 of 34 --

17
WINREVAIR: Strong launch execution demonstrates ability to maximize
value of pipeline
>$1B cumulative net sales since launch
2Q24 	3Q24 	4Q24 	1Q25 	2Q25
$1.7B
+40%
$336M
$280M
$200M
$70M
$149M
In the U.S., continued growth in new patient starts and TRx
• 	>1,600 new patients prescribed in the quarter
• 	>8,200 total patients prescribed since launch
• 	>6,500 patients with claims approved by payers started
treatment since launch
• 	~58,000 total prescriptions filled since launch
Strong breadth and depth of prescribers
• 	>1,200 physicians have written at least one prescription since
launch
• 	Steady increase in percentage of prescriptions for patients whose
background PAH therapies do not include a prostacyclin
Achieved coverage for >70% of lives since launch
Ex-U.S., progressing with approvals and reimbursement
• 	Expect to launch later in 3Q25 in Japan

-- 17 of 34 --

18
Animal Health: Growth across livestock and companion animal
Animal Health sales increased 11% to $1.6B
‒ 	Livestock sales grew 16%, driven by higher
demand across all species, as well as inclusion of
sales from recently expanded aqua portfolio
‒ 	Companion Animal sales growth of 6% reflects
price
‒ 	Growth in both segments benefitted from
improved supply
Growth rates exclude the impact of foreign exchange.
1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases.
2Q23 	2Q24 	2Q25
$1.5B
+2%
$1.5B
+6%1
$1.6B
+11%

-- 18 of 34 --

19
Q2 2025 non-GAAP financial results summary 1
$ in billions, except EPS amounts
1. The company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q2 2025 includes a charge of $0.07 per share
related to the closing of a license agreement with Hengrui Pharma. 3. Q2 2025 GAAP EPS of $1.76
Q2 2025 	Q2 2024 	Change Change
Ex-FX
Sales 	$15.8 	$16.1 	-2% 	-2%
Non-GAAP Gross Margin 	82.2% 	80.9% 	+1.3pts 	+1.4pts
Non-GAAP Operating
Expenses $6.6 	$6.2 	+7% 	+7%
Non-GAAP Tax Rate 	15.0% 	14.1% 	+0.9pts 	N/A
Non-GAAP EPS2,3 $2.13 	$2.28 	-7% 	-5%

-- 19 of 34 --

20
Updated 2025 financial outlook
1. Guidance does not assume any additional significant potential business development transactions, and does not include anticipated impact of the announced acquisition of Verona Pharma.
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$64.1B to $65.6B 	$64.3B to $65.3B • 	Now assumes ~0.5 percentage point FX headwind
• 	Implies +0% to +2% nominal (+1% to +2% ex-FX)
Non-GAAP
Gross Margin Rate ~82.0% 	~82.0% • 	Continues to assume ~$200M of costs related to tariffs,
pending the outcome of additional potential government
actions
Non-GAAP
Operating Expenses1 	$25.6B to $26.6B 	$25.6B to $26.4B
• 	Continues to assume $300M tech transfer milestone to
LaNova, which was completed in July, and includes $200M
upfront payment related to license agreement with
Hengrui Pharma
Other (Income) / Expense 	~$300M to ~$400M of expense 	~$300M to ~$400M of expense
Tax Rate 	~15.5% to 16.5% 	~15.0% to 16.0%
Shares Outstanding 	~2.51B 	~2.51B
Non-GAAP EPS1 	$8.82 to $8.97 	$8.87 to $8.97
• 	Continues to assume one-time charges related to tech
transfer milestone to LaNova and upfront payment to
Hengrui Pharma (now totaling ~$0.16 per share)
• 	Now assumes ~$0.15 FX headwind

-- 20 of 34 --

21
Key modeling considerations
GARDASIL
Family1
• 	In China, channel inventories remain elevated and demand continues to be soft, therefore will not resume shipments
through at least the end of this year
• 	Japan will be a more significant headwind to growth in second half as we lap increased vaccinations from catch-up cohort
Other
Revenue • 	Expect second half other revenue to be significantly lower due to negative impact from foreign exchange hedging program
Operating
Expenses • 	Expect second half operating expenses to be roughly evenly split between 3Q and 4Q, excluding business development
1. GARDASIL Family includes GARDASIL and GARDASIL 9

-- 21 of 34 --

22
Remain committed to balanced capital allocation strategy
Q2 Spend ($ in billions) 1
Continue to invest in our
pipeline and business, as well
as augment our pipeline with
value-enhancing business
development, while returning
cash to shareholders
1. Reflects quarter spend
2. Reflects R&D excluding Business Development
$3.2
$0.7
$2.1
$0.3
$1.3
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Capital allocation order of priority
2

-- 22 of 34 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
23

-- 23 of 34 --

24
Ohtuvayre is the first inhaled COPD maintenance treatment that
combines bronchodilatory and non-steroidal anti-inflammatory activity
First novel inhaled mechanism for maintenance
treatment of COPD in more than two decades
Dual inhibitor of phosphodiesterase 3 (PDE3) and
phosphodiesterase 4 (PDE4)
Improves symptoms of COPD for better breathing
and to reduce number of flare-ups
Source: Hubert et al, Trends Pharmacol Sci., 2024

-- 24 of 34 --

25
Important updates across cardiopulmonary portfolio
Announced positive topline results from Phase 3
CORALreef HeFH and CORALreef AddOn trials
– 	Both trials met primary and all key secondary endpoints,
demonstrating statistically significant and clinically
meaningful reductions in LDL-C versus placebo
(CORALreef HeFH) and versus other oral non-statin
therapies (CORALreef AddOn)
Results from three Phase 3 trials, including CORALreef
Lipids trial in broader hypercholesterolemia patient
population, will be presented at future scientific
congresses
Completed enrollment for Phase 3 CORALreef
Outcomes trial
Topline results for Phase 3 HYPERION trial in adults
recently diagnosed with PAH showed adding
WINREVAIR on top of background PAH therapy
significantly reduced risk of clinical worsening events
compared to background therapy alone
– 	Detailed results to be presented later this year
FDA granted priority review for sBLA to update label for
WINREVAIR based on ZENITH trial
– 	PDUFA date of October 25, 2025
Received approval from MHLW in Japan
WINREVAIR 	Enlicitide decanoate

-- 25 of 34 --

26
Building on our progress in infectious diseases
RSV 	Dengue 	HIV
FDA approved ENFLONSIA for
prevention of RSV lower respiratory tract
disease in infants born during or entering
first RSV season
– 	First and only option designed to protect
infants with same dose regardless of
weight
– 	ACIP recommended for use in infants
younger than eight months of age, and
inclusion in VFC1 program
Initiated first Phase 3 trial to evaluate
V181, investigational quadrivalent vaccine
for prevention of dengue disease caused
by any four dengue virus serotypes,
regardless of prior dengue exposure
Presented data at IAS2 from Phase 2 trial
evaluating MK-8527 for PrEP
– 	Potential to enable rapid onset of
protection within one hour of intake
without need for loading dose
– 	Support imminent initiation of Phase 3
EXPrESSIVE program
Presented data at IAS2 for combination of
islatravir and ulonivirine for once-weekly
treatment of adults living with HIV
FDA accepted NDA for combination of
doravirine and islatravir for once-daily
treatment of adults living with HIV-1 that
is virologically suppressed on
antiretroviral therapy
– 	PDUFA date of April 28, 2026
1. Vaccines for Children 2. International AIDS Society Conference on HIV Science

-- 26 of 34 --

27
Continuing to advance cancer care with a broad, differentiated portfolio
and pipeline
42 total approvals 2
10 earlier stage approvals 2
1. In collaboration with Daiichi Sankyo 2. Represents approvals in the U.S.
Showcased diverse pipeline at ASCO investor event
Three ongoing Phase 3 trials evaluating ifinatamab deruxtecan1
– 	IDeate-Esophageal01 in unresectable advanced or metastatic esophageal
squamous cell carcinoma
– 	IDeate-Prostate01 in metastatic castration-resistant prostate cancer
– 	IDeate-Lung02 in relapsed small cell lung cancer
KEYNOTE-689: Received FDA approval for KEYTRUDA as part of
perioperative treatment regimen for adult patients with resectable, locally
advanced HNSCC whose tumors express PD-L1 (CPS >1)
KEYNOTE-B96: Announced positive PFS and OS results for KEYTRUDA plus
chemotherapy with or without bevacizumab in certain patients with platinum-
resistant recurrent ovarian cancer
Received approval from MHLW in Japan for WELIREG for certain patients
with advanced RCC
Notable recent updates

-- 27 of 34 --

28
Key second half dates and milestones
Oncology
Subcutaneous pembrolizumab with berahyaluronidase alfa
• 	PDUFA date September 23rd
Cardiopulmonary
WINREVAIR
• 	PDUFA date October 25 th for FDA label update based on ZENITH trial
• 	Presentation of detailed findings from HYPERION trial
• 	Primary completion date in September for CADENCE trial in Cpc-PH due to HFpEF
Enlicitide decanoate
• 	Begin presenting detailed findings from CORALreef development program
Business Development
Verona Pharma
• 	Expect acquisition to close in 4Q25

-- 28 of 34 --

Q&A
Robert M. Davis
Chairman and Chief Executive Officer
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 29 of 34 --

30
Appendix

-- 30 of 34 --

31
Q2 2025 GAAP financial results summary
$ in billions, EPS amounts
1. 2Q25 GAAP results include $200 million charge, or $0.07 negative EPS impact, related to the closing of a license agreement with Hengrui Pharma
2. 2Q25 GAAP results include $779 million charge ($649 million related to 2025 restructuring program), or $0.25 negative EPS impact
Q2 2025 	Q2 2024 	Change 	Change Ex-FX
Sales 	$15.8 	$16.1 	-2% 	-2%
Operating Expenses
(SG&A and R&D)1 $6.7 	$6.2 	+7% 	+7%
Tax Rate 	11.4% 	9.1% 	+2.3pts 	N/A
GAAP EPS1,2 $1.76 	$2.14 	-18% 	-16%

-- 31 of 34 --

$12.6
$3.8
$8.0
$5.2
$3.4
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
~$21B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$11B in the U.S.
Billions
Over the past 12 months
Capital investments
2025 to 2029
Commitment to the dividend
32
Well-positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
Order of priority
1. Reflects R&D excluding Business Development
2. Includes BD payments reflected in operating cash flow
2
1
E
$1.84 	$1.88 	$1.92
$2.20 $2.44 $2.60 $2.76 $2.92 	$3.08 $3.24
2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025E
Dollars per share
+2% 	+2% 	+2%
+11%
+15%
+7% +6% +6% 	+5% +5%
Capital allocation: Trailing twelve months

-- 32 of 34 --

33
Driving value for patients and shareholders by progressing our pipeline
Key regulatory milestones since the last earnings call:
In the U.S.:
• 	FDA approved BRAVECTO QUANTUM as a once-yearly injectable product to treat and protect dogs from
fleas and ticks
• 	FDA approved KEYTRUDA as part of a neoadjuvant/adjuvant treatment regimen for adult patients with
resectable locally advanced HNSCC whose tumors express PD-L1 (CPS ≥1), based on KEYNOTE-689
• 	FDA approved WELIREG for the treatment of adults and pediatric patients 12 years and older with locally
advanced, unresectable, or metastatic PPGL
• 	FDA accepted for review an NDA for doravirine/islatravir, an investigational, once-daily, oral, two-drug
regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy
• 	FDA accepted and granted priority review for a new sBLA to update the U.S. product label for WINREVAIR
based on the Phase 3 ZENITH trial
• 	Following FDA approval, ACIP voted to recommend ENFLONSIA as an option for the prevention of RSV
lower respiratory tract disease in infants younger than 8 months of age who are born during or entering
their first RSV season
In the EU:
• 	EC approved NUMELVI for the treatment of pruritus associated with allergic dermatitis including atopic
dermatitis and treatment of clinical manifestations of atopic dermatitis for dogs
In China:
• 	NMPA approved KEYTRUDA in combination with LENVIMA plus TACE for the treatment of patients with
unresectable non-metastatic HCC
In Japan:
• 	MHLW approved AIRWIN (sotatercept) for the treatment of adults with PAH
• 	MHLW approved WELIREG as monotherapy for the treatment of adults with VHL disease-associated
tumors, and for adults with unresectable or metastatic RCC that has progressed after chemotherapy
• 	MHLW approved KEYTRUDA for metastatic HER2+ gastric cancer based on KEYNOTE-811
• 	MHLW approved KEYTRUDA for 1L unresectable advanced or metastatic malignant pleural mesothelioma
based on KEYNOTE-483
Key data & clinical advancements since the last earnings call:
Announced:
• 	Phase 3 HYPERION study evaluating WINREVAIR met primary
endpoint in recently diagnosed adults with PAH FC II or III at
intermediate or high risk of disease progression
• 	Phase 3 CORALreef HeFH and CORALreef AddOn trials evaluating
enlicitide decanoate met primary and all key secondary endpoints for
the treatment of adults with hyperlipidemia
• 	Phase 3 KEYNOTE-B96 trial evaluating KEYTRUDA met primary
endpoint of PFS in patients with platinum-resistant recurrent
ovarian cancer whose tumors expressed PD-L1 and in all comers, as
well as secondary endpoint of OS for patients whose tumors express
PD-L1
Presented data for:
• 	MK-8527, an investigational novel NRTTI, once-monthly pill, in
development for the prevention of HIV as pre-exposure prophylaxis
(PrEP) at IAS
• 	Broad oncology portfolio at ASCO, including for KEYTRUDA (KN-
D19, KN-564, KN-859, KN-A18, KN-689), WELIREG (LITESPARK-
004), sac-TMT (TROPION-Lung02, OptiTROP-Lung03), MK-1084
(KANDLELIT-001), and zilovertamab vedotin (waveLINE-003)
• 	WINREVAIR at ATS, including new clinical and outcomes data
Announced initiation of Phase 3 studies evaluating:
• 	MK-8527 (HIV PrEP), I-DXd (B7H3 ADC), V181 (Dengue), sac-TMT
(TROP2 ADC), MK-1084 (KRAS G12Ci)

-- 33 of 34 --

34
Broad and innovative pipeline to address significant unmet medical needs
As of August 5, 2025
Phase 3
Oncology
MK-1022 (patritumab deruxtecan) 1,3
Breast
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 2
CRC
NSCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan) 1
Esophageal
Prostate
SCLC
MK-2870 (sacituzumab tirumotecan) 1,3
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian
MK-3543 (bomedemstat)
Myeloproliferative Disorders
KEYTRUDA (MK-3475)
HCC (EU)
Ovarian
SCLC
MK-5684 (opevesostat)
Prostate
LYNPARZA (MK-7339) 1,2
NSCLC
SCLC
V940 (intismeran autogene) 1,2
Melanoma
NSCLC
MK-8527
HIV-1 PrEP
MK-8591A (doravirine + islatravir)
HIV-1 Infection (EU)
MK-8591D (islatravir + lenacapavir) 1,4
HIV-1 Infection
LAGEVRIO (MK-4482) 1,5
COVID-19 Antiviral (U.S.)
Infectious Disease
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
Cardiopulmonary
MK-0616 (enlicitide decanoate)
Hypercholesterolemia 	MK-30006
Diabetic Macular Edema
Ophthalmology
Phase 2
MK-2870 (sacituzumab
tirumotecan) 1,3
Biliary
Bladder
CRC
Neoplasm Malignant
Pancreatic
KEYTRUDA (MK-3475)
Prostate
MK-3475A (pembrolizumab +
berahyaluronidase alfa)
cSCC
Hematological Malignancies
MK-5909 (raludotatug
deruxtecan) 1
Biliary
Bladder
Cervical
CRC
Endometrial
Gastric
NSCLC
Ovarian
Pancreas
RCC
SCLC
WELIREG (MK-6482)
Breast
V940 (intismeran autogene) 1,2
Bladder
RCC
MK-1022 (patritumab
deruxtecan) 1,3
Biliary
Bladder
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreas
Prostate
MK-2400 (ifinatamab deruxtecan) 1
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreas
Oncology
Infectious Disease
MK-8591B (islatravir+ulonivirine)
HIV-1 Infection
MK-5475
PH-COPD
MK-6024 (efinopegdutide)
MASH
WINREVAIR (MK-7962)
Pulmonary Hypertension due to
Left Heart Disease
Cardiopulmonary
MK-7240 (tulisokibart)
Hidradenitis Suppurativa
Systemic Sclerosis
Immunology
MK-1167
Alzheimer’s Disease
MK-2214
Alzheimer’s Disease
Neuroscience
Under regulatory review
Oncology
KEYTRUDA (MK-3475)
HNSCC (EU, JPN)
MK-3475A (pembrolizumab +
berahyaluronidase alfa)
Previously Approved Solid Tumors (U.S.)
Previously Approved Tumors (EU)
Vaccines
CAPVAXIVE (V116)
Pneumococcal Vaccine Adult (JPN)
Infectious Disease
ENFLONSIA (MK-1654)
Respiratory Syncytial Virus (EU, JPN)
MK-8591A (doravirine + islatravir)
HIV-1 Infection (U.S., JPN)
Cardiopulmonary
WINREVAIR (MK-7962)
Pulmonary Arterial Hypertension (ZENITH)
(US)
1. Being developed in a collaboration 2. Being developed in combination with KEYTRUDA 3. Being developed as monotherapy and/or in combination with KEYTRUDA 4. On partial clinical hold for higher doses of islatravir than those used in current clinical trials
5. Available in the U.S. under Emergency Use Authorization 6. Program is in Phase 2/3 study
MK-8748
Eye Disorders
Ophthalmology
V181
Dengue Fever Virus
Vaccines

-- 34 of 34 --